Clinton Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Clinton Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-5,324	Closed	-$2M	–	475
2017 Q4	$2M	Buy	+5,324	New	+$2.16M	0.18%	179
2016 Q4	–	Sell	-16,499	Closed	-$6.63M	–	967
2016 Q3	$6.63M	Buy	16,499 +13,733	+496%	+$5.51M	0.31%	86
2016 Q2	$966K	Sell	2,766 -5,263	-66%	-$2.03M	0.04%	491
2016 Q1	$2.89M	Buy	8,029 +5,220	+186%	+$2.15M	0.17%	174
2015 Q4	$1.52M	Buy	2,809 +2,304	+456%	+$1.25M	0.12%	260
2015 Q3	$235K	Buy	+505	New	+$271K	0.02%	597
2015 Q2	–	Sell	-2,051	Closed	-$926K	–	682
2015 Q1	$926K	Buy	+2,051	New	+$869K	0.24%	120
2014 Q2	–	Sell	-722	Closed	-$217K	–	407
2014 Q1	$217K	Sell	722 -490	-40%	-$151K	0.08%	308
2013 Q4	$334K	Sell	1,212 -355	-23%	-$102K	0.11%	219
2013 Q3	$490K	Buy	+1,567	New	+$412K	0.15%	188

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Clinton Group's REGN Position: Q1 2018 in Review

Clinton Group sold out of Regeneron Pharmaceuticals (REGN) in Q1 2018, closing a stake of 5,324 shares — an estimated $2M sold.

Clinton Group first reported a position in REGN in Q3 2013 and held it in 10 quarters. The position peaked at $6.63M in Q3 2016. 620 funds tracked by Wall St. Rank hold REGN as of Q1 2018.

Clinton Group reported no remaining Regeneron Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Clinton Group sold 5,324 Regeneron Pharmaceuticals shares in Q1 2018, an estimated $2M.
Clinton Group first reported a position in Regeneron Pharmaceuticals in Q3 2013 and held it in 10 quarters.
Clinton Group's Regeneron Pharmaceuticals position peaked at $6.63M in Q3 2016.
620 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2018.

Based on Clinton Group's 13F filing for Q1 2018, filed 14 May 2018.